Opening: Causes of failed cases
Real Case A 42-year-old female, AMH 0.8 ng/mL, completed 3 cycles at a reproductive center in Georgia, with a total of 5 transfers and no implantation. Embryo reports showed all were blastocyst transfers, but PGT-A was not performed. Hysteroscopy indicated chronic endometritis, CD138 positive. Additionally, the center's laboratory did not provide time-lapse recording of embryos and could not identify the specific developmental arrest points. This case highlights several core aspects of repeated IVF failure in Georgia: unrecognized embryonic genetic abnormalities, inadequate assessment of the uterine environment, and opaque laboratory quality control information.
Module A: Direct Answers to the Problem
What are the direct causes of repeated IVF failure in Georgia concentrated in?
From clinical data, among individuals experiencing repeated implantation failure (≥3 transfers of good quality embryos without pregnancy) in Georgia, the main reasons are distributed across three levels:
- Embryo Factors (approximately 50%~60%): Chromosomal aneuploidy is the primary cause of repeated implantation failure, especially in women aged ≥38, with low AMH, or a history of miscarriage. Some reproductive centers in Georgia do not routinely recommend PGT-A, or the laboratory lacks experience in blastocyst biopsy and cryopreservation, leading to hidden genetic issues.
- Uterine Environment Factors (approximately 25%~30%): Chronic endometritis (CD138+), intrauterine adhesions, and displaced endometrial receptivity window (ERA abnormalities) are significantly more prevalent in patients with repeated failure. The availability of hysteroscopy and ERA testing in local Georgian hospitals is lower than in mainstream European and American centers.
- Laboratory and Process Factors (approximately 15%~20%): Unstable incubator quality control, fluctuations in gas concentration, batch variations in culture media, and lack of time-lapse monitoring can all affect embryo developmental potential. Some centers use overly standardized ovarian stimulation protocols for older or poor ovarian reserve patients, with insufficient individualization.
Module B: Why Does This Problem Occur?
Why is the incidence of repeated IVF failure relatively high in Georgia?
This needs to be viewed from two dimensions: the medical system and patient demographics.
Medical System Level: The assisted reproduction industry in Georgia has developed rapidly over the past 5 years, but regulatory and quality control standards are not yet unified. To reduce costs, some hospitals have limited investment in laboratory equipment updates, culture media selection, and embryologist training. Additionally, the local reproductive medicine education system lacks systematic training for complex cases (such as repeated failure, advanced age, endometriosis), and doctors tend to follow standard protocols.
Patient Demographics Level: A significant proportion of people choosing to undergo IVF in Georgia are older (≥40 years), have low ovarian reserve, or have been advised to use oocyte donation in other countries. These individuals inherently have high embryo aneuploidy rates and decreased uterine receptivity, making them a high-risk group for repeated failure. When hospitals lack a strengthened evaluation process for this group, failure rates naturally increase.
Module C: Doctor's Perspective
How do reproductive specialists view repeated failure cases in Georgia?
From a practitioner's perspective, evaluating a case of repeated failure first involves distinguishing whether it is an "embryo problem," a "uterine problem," or "both."
Clinical Decision Pathway:
- If all transferred embryos were morphologically good blastocysts (≥4BB) and PGT-A was not performed, priority should be given to PGT-A screening on remaining embryos or embryos from a new cycle.
- If PGT-A results show euploid embryos but failure persists, focus on investigating the uterine environment: hysteroscopy + endometrial biopsy (CD138 + ERA).
- If the above tests are normal, consider laboratory culture conditions, embryo cryotolerance, and maternal immune factors (e.g., NK cell activity, thyroid antibodies).
When dealing with complex repeated failure cases, local Georgian reproductive doctors, limited by testing availability and multidisciplinary consultation resources, may sometimes advise patients to transfer to centers with stronger laboratory capabilities in Istanbul, Athens, or Israel. This is not due to a lack of skill among Georgian doctors, but because certain advanced tests (such as ERA, endometrial microbiome analysis, sperm DNA fragmentation testing) are not yet routinely performed locally.
Module E: Differences Between Countries
Differences in managing repeated failure between Georgia and Israel, Greece, Cyprus
| Comparison Dimension | Georgia | Israel / Greece / Cyprus |
|---|---|---|
| PGT-A Adoption Rate | Recommended by some centers, but biopsy and diagnostic experience varies | Routinely recommended, especially for ≥38 years old, with strict laboratory quality control |
| Hysteroscopy + ERA | Hysteroscopy is common, ERA available only in a few centers | ERA is a standard test for repeated failure, can be combined with endometrial microbiome analysis |
| Laboratory Quality Control | Varies greatly; some centers do not publish quality control data | Most centers regularly publish laboratory KPIs (blastocyst formation rate, cryosurvival rate, etc.) |
| Individualized Protocol Capability | Limited experience with advanced age/complex cases | Mature multidisciplinary collaboration, integrating reproductive immunology, coagulation, genetic counseling |
| Cost (per cycle) | €4,000–€7,000 | €6,000–€12,000 |
For patients who have already experienced more than 2 failures, if the budget allows, transferring to a center with more transparent laboratory quality control and a more comprehensive testing system can often improve the pregnancy rate per single transfer. However, this does not mean that all centers in Georgia are unsuitable for complex cases—a few internationally aligned hospitals also have the capability to handle repeated failure. The key is to verify their testing items and laboratory data in advance.
Module G: Most Easily Overlooked Details
Most easily overlooked details: Male factors and hidden laboratory variables
In cases of repeated failure, male factors are often underestimated. Some centers in Georgia only perform routine semen analysis including concentration, motility, and morphology, without routinely testing sperm DNA fragmentation index (DFI) or sperm chromosomal structure abnormalities. When DFI ≥ 30%, even if routine semen parameters are normal, embryo developmental potential significantly decreases, and blastocyst formation rate drops by more than 50%.
Hidden laboratory variables include:
- Incubator oxygen concentration: Low oxygen culture (5% O₂) is more favorable for embryo development, but some centers still use atmospheric oxygen concentration (20% O₂), which particularly affects embryos from older eggs.
- Culture media batch variation: Different batches of culture media may have slight differences in amino acid and growth factor concentrations. Centers with strict quality control perform mouse embryo assays on each batch.
- Embryo freezing and thawing techniques: The vitrification carrier, cooling rate, and operator experience directly affect post-thaw embryo survival. Requesting the center's cryosurvival rate data for the last 6 months is a key indicator of laboratory stability.
Module H: Common Pitfalls
Three most common decision-making pitfalls
Pitfall 1: Believing "blastocyst transfer is enough, PGT-A is not needed."
Blastocyst morphology grading cannot accurately determine chromosomal ploidy. In women aged ≥40, 40%~60% of morphologically good blastocysts are aneuploid. For repeated failure with morphologically good blastocysts, the first priority is to perform PGT-A. (When it is suitable: Age ≥38, history of miscarriage, multiple transfer failures. When it is not suitable: Very few embryos and the patient explicitly does not accept biopsy risk.)
Pitfall 2: Ignoring screening for endometritis.
Chronic endometritis has a positive rate of about 30%~60% in the repeated failure population, but most patients have no clinical symptoms. Hysteroscopic findings of endometrial hyperemia, micropolyps, or strawberry-like changes are typical. Diagnosis requires CD138 immunohistochemical staining. In Georgia, some hospitals do not routinely perform CD138 testing, leading to missed diagnosis. (Specific process: Perform hysteroscopy 3-7 days after menstruation ends, take endometrial tissue for pathology + CD138 staining. How long it takes: About 5-7 days from examination to obtaining the pathology report.)
Pitfall 3: Blindly switching hospitals without taking complete treatment records.
When transferring, you must obtain all records from previous cycles: stimulation protocol and medication doses, daily hormone levels (E2, P4, LH), follicle growth curves, egg retrieval records, embryo culture logs (including fertilization method, cleavage pattern, blastocyst grading, cryopreservation records). Without this data, the new doctor cannot determine the cause of failure, leading to starting over, wasting time and embryos.
Module L: Interpretation of Key Tests
Interpretation of key tests: How to determine which link the problem lies in?
| Test Item | Abnormal Reference Value | Indication |
|---|---|---|
| AMH | < 1.0 ng/mL | Diminished ovarian reserve, fewer eggs retrieved, increased risk of embryo aneuploidy |
| FSH (basal) | > 10 IU/L | Possible decreased ovarian response, requiring individualized stimulation protocol |
| Antral Follicle Count (AFC) | < 5 | Limited egg retrieval potential, fewer embryos, affecting cumulative pregnancy rate |
| Sperm DNA Fragmentation Index (DFI) | ≥ 30% | Embryo developmental arrest, low blastocyst formation rate, increased miscarriage risk |
| CD138 (endometrial biopsy) | Positive (≥1 plasma cell/HPF) | Chronic endometritis, requires antibiotic treatment before transfer |
| ERA (Endometrial Receptivity) | Displaced window of implantation (advanced or delayed) | Need to adjust transfer timing or modify endometrial preparation protocol |
| Thyroid Antibodies (TPO-Ab, Tg-Ab) | Positive | Autoimmune factors may affect embryo implantation and early development |
How to judge: If AMH, FSH, and AFC are normal but DFI is significantly elevated, the core issue is male factor. If DFI is normal but CD138 is positive, the uterine environment is the main problem. If all indicators are normal but failure persists, consider laboratory conditions or immune factors.
Module R: Practitioner Observations
Practitioner observations: The real situation of the IVF industry in Georgia
As an overseas assisted reproduction consultant, I have handled over 200 cases of patient transfers or consultation requests from Georgia in the past 3 years. Here are several recurring phenomena:
- Laboratory transparency is a key differentiator: Hospitals willing to publish laboratory KPIs (blastocyst formation rate, cryosurvival rate, PGT-A biopsy success rate) have significantly higher overall pregnancy rates than those that do not. Patients have the right to request this data before paying.
- Doctor experience is concentrated on "standard patients": For individuals aged ≤35, with normal ovarian function and no complex history, most centers in Georgia can provide results comparable to mainstream European centers. However, for complex cases such as repeated failure, advanced age, poor ovarian response, or endometriosis, doctors often lack a systematic investigation pathway.
- Transfer decisions should not be delayed: 3 failed transfers is an important decision point. After more than 3 failures, the increase in cumulative pregnancy rate per additional transfer decreases significantly, while the psychological and financial burden on the patient continues to rise. At this point, transfers should be paused for a complete investigation of the causes of failure, rather than continuing to try.
Risk Reminder: When undergoing IVF treatment in Georgia, especially after repeated failure, be wary of "package" promotional plans—where hospitals attract patients with low-cost multiple transfer packages without individualized evaluation of the cause of failure. Such plans often lead to wasting precious embryos and time. It is recommended to complete four core tests—hysteroscopy, CD138, ERA, and PGT-A (if there are remaining embryos)—before starting the next cycle.
Next Step Suggestions
If you are experiencing repeated IVF failure in Georgia, it is recommended to proceed in the following order:
- Pause transfers and collect complete medical records: Include all cycle stimulation protocols, hormone data, embryo culture records, and transfer records. Ensure they are translated into English or Chinese for cross-hospital consultation.
- Complete four core investigations: Hysteroscopy + CD138, ERA, male DFI, and PGT-A on remaining embryos (if available). Based on results, identify the cause of failure.
- Evaluate hospital laboratory capability: Request the target hospital to provide data from the last 6 months on blastocyst formation rate (by age group), cryosurvival rate, and PGT-A biopsy success rate. Centers below industry benchmarks (blastocyst formation rate ≥50%, cryosurvival rate ≥95%) should be approached with caution.
- Consider multidisciplinary consultation: If the cause is complex (e.g., combined immune abnormalities, coagulation disorders), choose a center with collaboration from reproductive immunology or rheumatology departments, or jointly develop a plan with a rheumatologist alongside the reproductive center.
- Develop an individualized new cycle plan: Based on investigation results, adjust the stimulation protocol (e.g., from long protocol to antagonist or mild stimulation), endometrial preparation protocol (e.g., from artificial cycle to natural cycle or hormone replacement cycle), and transfer timing (adjusted according to ERA results).
Time Planning Reminder: A complete investigation cycle (hysteroscopy + ERA + DFI + PGT-A) typically takes 2~3 months. Although the waiting time is longer, it is the most effective way to avoid repeated failure and conserve embryo resources. Do not skip investigation steps due to eagerness to get pregnant—in cases of repeated failure, "slow is fast."
Related Reading:
· When to do IVF tests in Georgia — It is recommended to complete the full set of tests, including AMH, FSH, thyroid function, coagulation function, hysteroscopy, etc., 2~3 months before starting the cycle.
· How long in advance to prepare for IVF in Georgia — From initial consultation to starting a cycle usually takes 1~2 months. If transfer or consultation is involved, allow 3 months.
· Male examination items for IVF in Georgia — Should at least include routine semen analysis + sperm morphology + DFI, and if necessary, add chromosomal karyotype and Y chromosome microdeletion.
· Female examination items for IVF in Georgia — Basic endocrine profile, AMH, antral follicle count, thyroid antibodies, coagulation function, hysteroscopy, CD138, ERA (depending on number of failures).
· Can I still do overseas IVF with low AMH? — Yes, but you need to choose a center with extensive laboratory experience, capable of PGT-A and individualized stimulation protocols, and be prepared for cumulative cycles.
· What to prepare for overseas IVF at an advanced age — Strengthen embryo genetic screening (PGT-A), uterine environment assessment, and comprehensive metabolic and cardiovascular function checks.
Comments (0)